Arcturus’ proprietary unlocked nucleomonomer agent (UNA) Oligomer technology can be used to make all types of RNA medicines more stable, safe and specific.
UNA nucleotides can be incorporated into either DNA or RNA using standard automated synthesis procedures. UNAs have a similar structure to natural nucleic acids so do not change RNA function or tertiary structure. In partnered clinical trials, RNA medicines incorporating UNAs have been shown to be safe and effective in human patients.
UNAs are not recognized by the immune system so do not stimulate an immune response and are not broken down as quickly as natural RNA. Therefore RNA medicines incorporating UNAs cause less toxicity, have less off-target effects, are more potent and have a longer half-life than regular RNA medicines.
February 12, 2018
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
February 2, 2018
Arcturus Therapeutics Appoints Mark Herbert as Interim President
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics